The raphe nuclei are the seam of serotonin-synthesizing neurons along the brainstem's midline — the brain's entire source of forebrain serotonin. From the rostral group (upper pons and midbrain) axons climb to cortex, striatum, and limbic system, setting mood, sleep architecture, and behavioral inhibition; the caudal group descends to the spinal cord, dampening pain. Antidepressant pharmacology works here: SSRIs raise serotonin at these neurons' terminals, and psychedelic and antipsychotic mechanisms thread through the same receptors.
Location
Midline brainstem from midbrain to medulla (the "raphe" or seam)
Key Components
Rostral group (nucleus raphe dorsalis, centralis superior, median raphe → forebrain); caudal group (raphe magnus, pallidus, obscurus → cerebellum, spinal cord)
The dorsal raphe nucleus (in the midbrain, beside the cerebral aqueduct) is the largest serotonin source — most of the cortical supply; the median raphe supplies the hippocampus and septum.
Raphe neurons fire tonically in wakefulness, slow in NREM, and near-silence in REM — serotonin's vigilance state coding.
Subsets co-release glutamate or GABA — the serotonergic label simplifies a chemically mixed population.
Circuitry & Connections
The ascending serotonergic pathway joins the medial forebrain bundle — diffuse cortical innervation, volume-transmission style.
Descending: raphe magnus → dorsal horn enkephalin/GABA interneurons — the periaqueductal gray-raphe-spinal analgesia system that morphine recruits.
Reciprocal control by the locus coeruleus and prefrontal cortex — arousal and top-down state setting.
Function
Mood and affect: serotonin tone sets behavioral inhibition and patience for delayed reward — the waiting circuit (Miyazaki's work).
Sleep architecture: serotonin neurons quiet as sleep deepens — the wakefulness monoamine arm of the flip-flop.
Pain control: descending inhibition of nociception — the endogenous analgesia pathway's final serotonin link.
Clinical Relevance
Depression and SSRIs: the serotonin hypothesis of depression and its drugs — acute synaptic serotonin rises immediately but mood lifts weeks later (receptor adaptation, the disputed-but-treating story).
Psychedelics: psilocin and LSD are 5-HT2A agonists — the raphe-serotonin system's pharmacology, now in depression trials.
Serotonin syndrome: serotonergic drug excess — clonus, hyperthermia, agitation — the system's toxicology.